Jack A. Khattar - 13 Mar 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
President, CEO, Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
13 Mar 2026
Net transactions value
-$1,763,124
Form type
4
Filing time
16 Mar 2026, 16:08:19 UTC
Previous filing
10 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Khattar Jack A. President, CEO, Director C/O SUPERNUS PHARMACEUTICALS INC., 9715 KEY WEST AVENUE, ROCKVILLE /s/ Timothy C. Dec, as attorney-in-fact 16 Mar 2026 0001539937

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Other +12,500 +1% 1,241,144 13 Mar 2026 Direct F1
transaction SUPN Common Stock Other -12,500 -1.2% 993,100 13 Mar 2026 By the KBT Trust F1
transaction SUPN Common Stock Sale $1,209,072 -24,138 -2.4% $50.09 968,962 13 Mar 2026 By the KBT Trust F2, F3
transaction SUPN Common Stock Sale $547,842 -10,742 -1.1% $51.00 958,220 13 Mar 2026 By the KBT Trust F2, F4
transaction SUPN Common Stock Sale $6,210 -120 -0.01% $51.75 958,100 13 Mar 2026 By the KBT Trust F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Reporting Person is filing this Form 4 to reflect the fact that 12,500 shares were transferred from the KBT Trust to the Reporting Person on March 13, 2026 without consideration and are now owned directly.
F2 Transaction made pursuant to a 10b5-1 trading plan adopted December 12, 2025.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.63 to $50.62. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.63 to $51.54. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.